Why the study?
Does serum cardiac troponin T (cTnT) measurement improve the diagnosis of myocardial injury in newborns?
Does serum cardiac troponin T (cTnT) measurement improve the diagnosis of myocardial injury in newborns?
The study evaluates the utility of serum cardiac troponin T and CK-MB mass concentration as specific biochemical markers for diagnosing myocardial injury in newborns.
Answers are grounded in this paper and cite their sources.
cTnT may aid neonatal myocardial injury diagnosis; leaves open routine adoption pending validation studies.
In neonates, acute perinatal asphyxia may lead to ischemic myocardial damage (1). In some cases, subendocardial infarction has been documented (2). Generally, diagnosis of the myocardial injury (MI) is based on clinical findings, suggestive electrocardiographic and echocardiographic patterns (3), decrease in myocardial uptake of thallium (4), and classical creatine kinase (CK)-MB isoenzyme measurement (5). However, CK-MB in serum cannot be regarded as a cardiac-specific marker in the neonate, and extreme caution should be used in the interpretation of increased CK-MB activity during this period (6). Cardiac troponin T (cTnT), the structural protein that binds the troponin complex to the tropomyosin molecular strand, has recently been proposed as a more specific biochemical marker for diagnosis of myocardial infarction in the adult population (7). Here we evaluated the use of cTnT measurement in serum in the diagnosis of MI in newborns, as well as that of the determination of CK-MB mass concentration by a sensitive and specific monoclonal anti-CK-MB antibody-based immunoassay.
No takes yet. Share an insight, caveat, or question.
Panteghini et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: